Yen-Ling Peng
Overview
Explore the profile of Yen-Ling Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tien F, Yao C, Cheng-Hong Tsai X, Lo M, Chen C, Lee W, et al.
Blood Cancer J
. 2024 Jan;
14(1):15.
PMID: 38253683
Acute myeloid leukemia (AML) with CEBPA bZIP in-frame mutations (CEBPA) is classified within the favorable-risk group by the 2022 European LeukemiaNet (ELN-2022). However, heterogeneous clinical outcomes are still observed in...
2.
Peng Y, Chang C, Wei S, Huang T, Tai W, Hsu W, et al.
J Formos Med Assoc
. 2023 Apr;
122(10):1042-1049.
PMID: 37019722
Background: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions...
3.
Lo M, Cheng-Hong Tsai X, Lin C, Tien F, Kuo Y, Lee W, et al.
Am J Hematol
. 2023 Mar;
98(5):760-769.
PMID: 36861732
The European LeukemiaNet (ELN) recently proposed a revised recommendation for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized as ELN-2022. However, validation in a large real-world...
4.
Cheng-Hong Tsai X, Sun K, Lo M, Tien F, Kuo Y, Tseng M, et al.
Blood Cancer J
. 2023 Jan;
13(1):4.
PMID: 36599822
A set of myelodysplasia-related (MDS-R) gene mutations are incorporated into the 2022 European LeukemiaNet risk classification as adverse genetic factors for acute myeloid leukemia (AML) based on their poor prognostic...
5.
Lee W, Lin C, Wang Y, Yao C, Kuo Y, Tseng M, et al.
Hematol Oncol
. 2022 Nov;
41(3):463-473.
PMID: 36420747
Myelodysplastic syndromes (MDS) are a group of clinically and genetically diverse diseases that impose patients with an increased risk of leukemic transformation. While MDS is a disease of the elderly,...
6.
Tien F, Tsai C, Huang S, Liu J, Chen C, Kuo Y, et al.
Bone Marrow Transplant
. 2021 Oct;
57(1):95-105.
PMID: 34671120
The mutant burden of FLT3-ITD modulates its prognostic impact on patients with acute myeloid leukemia (AML). However, for patients with low allelic ratio (AR) FLT3-ITD (FLT3-ITD, AR < 0.5), clinical...
7.
Wang Y, Hou H, Lin C, Kuo Y, Yao C, Hsu C, et al.
Blood Adv
. 2021 Oct;
5(22):4535-4548.
PMID: 34614508
Aside from cell intrinsic factors such as genetic alterations, immune dysregulation in the bone marrow (BM) microenvironment plays a role in the development and progression of myelodysplastic syndromes (MDS). However,...
8.
Lee H, Peng Y, Whang L, Liao J
Materials (Basel)
. 2021 Jul;
14(12).
PMID: 34207811
Steel slag is a secondary product from steelmaking process through alkaline oxygen furnace or electric arc furnace (EAF). The disposal of steel slag has become a thorny environmental protection issue,...
9.
Tsai C, Tang J, Tien F, Kuo Y, Wu D, Lin C, et al.
Blood Adv
. 2021 May;
5(10):2456-2466.
PMID: 33999144
Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test...
10.
Tsai C, Yao C, Tien F, Tang J, Kuo Y, Chiu Y, et al.
EBioMedicine
. 2019 Jan;
40:240-250.
PMID: 30662003
Background: Expression of long non-coding RNAs (lncRNAs) has recently been recognized as a potential prognostic marker in acute myeloid leukemia (AML). However, it remains unclear whether incorporation of the lncRNAs...